Canada markets closed

Lennar Corporation (LEN-B)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
63.97+1.87 (+3.01%)
At close: 04:00PM EDT
63.97 -0.10 (-0.16%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close62.10
Open61.04
Bid62.48 x 900
Ask65.40 x 1800
Day's Range61.46 - 64.07
52 Week Range52.67 - 96.42
Volume84,595
Avg. Volume120,775
Market Cap21.923B
Beta (5Y Monthly)1.47
PE Ratio (TTM)4.39
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.50 (2.42%)
Ex-Dividend DateJul 06, 2022
1y Target EstN/A
  • GlobeNewswire

    ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

    LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA Base Editing Technologies for Precision MedicinesPresenter: Ge

  • GlobeNewswire

    ProQR Announces First Quarter 2022 Operating and Financial Results

    Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and provide an update in Q3/early Q4Enrollment is ongoing in Sirius, a Phase 2/3 trial of ultevursen (QR-421a), for USH2A-mediated Usher syndrome and retinitis pigmentosaProQR is accelerating the development of its Axiomer® RNA base-edit

  • GlobeNewswire

    ProQR to Participate in the Kempen Life Sciences Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will participate in the Kempen Life Sciences Conference on April 20, 2022. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA tech